RNA Drug Substance Manufacturing
RNA drug substance manufacturing involves the controlled production, purification, concentration, and quality assessment of RNA active pharmaceutical ingredients for downstream formulation and drug product manufacturing. Compared with chemically synthesized oligonucleotides, RNA drug substances such as mRNA typically involve enzymatic synthesis and require dedicated control of template quality, transcription efficiency, RNA integrity, capping, impurities, and product stability.
Protheragen provides RNA Drug Substance Manufacturing Services supporting the production of RNA drug substances across different stages of nucleic acid drug development. Manufacturing activities cover RNA synthesis, downstream processing, purification, concentration, drug substance preparation, analytical testing, and scale-up to support preclinical, clinical, and later-stage development.
Overview of RNA Drug Substance Manufacturing
RNA drug substance manufacturing focuses on producing RNA molecules with defined identity, integrity, purity, concentration, and other quality attributes required for subsequent drug product development. The manufacturing process is designed around the characteristics of the RNA molecule, including sequence, length, structure, modifications, intended function, and formulation strategy.
For mRNA-based therapeutics, manufacturing commonly involves preparation of a DNA template followed by in vitro transcription (IVT), RNA processing, purification, concentration, and final drug substance preparation. Depending on the product design, additional steps such as 5′ capping, poly(A) tailing, enzymatic treatment, buffer exchange, and removal of residual template DNA, enzymes, nucleotides, and other process-related impurities are incorporated into the manufacturing process.
RNA drug substance manufacturing is closely connected with downstream formulation. The physical form, concentration, buffer composition, storage conditions, and quality requirements of the RNA drug substance are established in consideration of subsequent aqueous, lyophilized, or LNP-based drug product development.
Fig.1 Process of In Vitro Transcription (IVT) and DS purification and upstream processes to produce the DNA template. (Webb C, et al., 2022)
Our Services
RNA drug substance manufacturing integrates RNA synthesis, downstream processing, purification, concentration, analytical testing, and quality control into a controlled production workflow. Key services focus on RNA integrity, impurity clearance, process consistency, scalability, and drug substance quality.
RNA Synthesis and In Vitro Transcription
RNA synthesis produces the target RNA sequence using an appropriate transcription system and controlled reaction conditions. For mRNA drug substances, IVT parameters are optimized and controlled to support transcription efficiency, RNA integrity, and consistent product quality.
Services include:
- In vitro transcription (IVT)
- RNA sequence transcription
- Nucleotide substrate preparation
- Transcription reaction control
- mRNA synthesis
DNA Template Preparation
DNA templates provide the sequence information required for RNA transcription and are prepared with appropriate quality attributes for manufacturing. Template preparation includes DNA production, purification, sequence verification, and quality control.
Services include:
- DNA template preparation
- Template purification
- Sequence verification
- Template quality testing
- Residual DNA control
RNA Processing and Capping
Post-transcriptional processing establishes the required molecular characteristics of the RNA drug substance. For mRNA, 5′ capping and poly(A) tail formation are controlled to support RNA stability and biological activity.
Services include:
- 5′ capping
- Co-transcriptional capping
- Post-transcriptional capping
- Poly(A) tailing
- RNA processing
RNA Purification and Impurity Removal
Purification removes unwanted RNA species and process-related impurities generated during RNA synthesis. Downstream processing targets truncated transcripts, double-stranded RNA, residual DNA, proteins, enzymes, nucleotides, and other contaminants.
Services include:
- RNA purification
- Double-stranded RNA removal
- Residual DNA removal
- Protein and enzyme removal
- Truncated RNA clearance
Concentration and Buffer Exchange
Concentration and buffer exchange establish the required RNA drug substance concentration and chemical environment. Controlled downstream processing reduces residual low-molecular-weight components and prepares RNA for final drug substance preparation or formulation.
Services include:
- RNA concentration
- Ultrafiltration and diafiltration
- Buffer exchange
- Desalting
- RNA solution preparation
RNA Drug Substance Preparation
Purified RNA is converted into the defined drug substance form required for downstream development and manufacturing. Preparation includes concentration adjustment, buffer conditioning, bulk handling, filling, and controlled storage.
Services include:
- RNA bulk drug substance preparation
- Concentration adjustment
- Buffer conditioning
- Bulk solution preparation
- Drug substance filling and storage
Analytical Testing and Quality Control
Analytical testing evaluates RNA identity, integrity, purity, concentration, molecular characteristics, and process-related impurities. Quality control supports in-process monitoring, characterization, specification development, and batch release.
Services include:
- RNA identity testing
- RNA integrity analysis
- Purity and related substance testing
- RNA concentration determination
- Double-stranded RNA analysis
- Residual DNA testing
Scale-Up and Manufacturing
RNA manufacturing processes are transferred from development scale to larger production scales with appropriate control of reaction parameters, purification capacity, material requirements, and product quality. GMP-oriented manufacturing supports clinical and later-stage drug substance supply.
Services include:
- RNA process scale-up
- Pilot-scale manufacturing
- RNA drug substance production
- Clinical supply manufacturing
- Manufacturing process transfer
Oligonucleotide API Manufacturing Process
RNA drug substance manufacturing follows a controlled sequence of upstream and downstream operations designed to produce consistent and well-characterized RNA material.
RNA Drug Substance Manufacturing for Different RNA Modalities
mRNA Drug Substance
mRNA manufacturing involves DNA template preparation, IVT, RNA processing, purification, concentration, and drug substance preparation. Manufacturing controls focus on RNA integrity, capping efficiency, poly(A) characteristics, dsRNA impurities, residual DNA, and other product-specific quality attributes.
Self-Amplifying RNA
Self-amplifying RNA contains additional genetic elements that enable intracellular RNA amplification. Manufacturing requires control of the larger RNA molecule, transcription performance, integrity, purification, and product-specific impurities.
Circular RNA
Circular RNA manufacturing requires production and processing strategies appropriate for circular RNA formation and purification. Analytical characterization focuses on confirming circular structure, removing linear RNA species, and controlling process-related impurities.
Other Therapeutic RNA
Other RNA drug substances are manufactured according to their sequence, structural characteristics, chemical modifications, biological function, and intended formulation strategy.
RNA Drug Substance Manufacturing and Downstream Formulation
RNA drug substance manufacturing is closely connected with subsequent drug product development. The characteristics of the purified RNA-including concentration, buffer composition, purity, integrity, and stability-directly influence downstream formulation development.
The manufacturing pathway can therefore connect:
RNA Drug Substance Manufacturing → Aqueous Formulation → Lyophilized Formulation → LNP Formulation → Drug Product Manufacturing
For mRNA and other RNA therapeutics, LNP formulation provides a widely used delivery strategy, while aqueous and lyophilized formulations provide additional approaches depending on product characteristics and stability requirements.
Why Choose Protheragen
- Integrated RNA CMC Support
RNA drug substance manufacturing is connected with process development, analytical development, formulation, drug product manufacturing, and stability studies within an integrated CMC workflow.
- RNA Manufacturing Expertise
Manufacturing processes are designed around the specific characteristics of RNA drug substances, including sequence, length, structure, modifications, and formulation requirements.
- Controlled Downstream Processing
RNA purification, concentration, buffer exchange, and bulk preparation are integrated into the manufacturing workflow to support consistent drug substance quality.
- Analytical and Quality Support
Analytical testing supports RNA identity, integrity, purity, concentration, and process-related impurity control throughout manufacturing.
- Scale-Up and Clinical Supply
Manufacturing processes are structured for progression from development-scale production to clinical-stage and later-stage supply.
- GMP-Oriented Manufacturing
Manufacturing processes, documentation, quality controls, and batch testing are aligned with applicable development-stage and GMP requirements.
RNA drug substance manufacturing requires coordinated control of synthesis, RNA processing, purification, concentration, analytical testing, and storage. A well-controlled manufacturing process establishes the foundation for consistent RNA quality and supports subsequent formulation and drug product development. Protheragen provides an integrated pathway from RNA process development to RNA drug substance manufacturing and downstream formulation, supporting RNA therapeutic programs from early development through clinical and later-stage manufacturing. Contact us to explore RNA drug substance manufacturing solutions designed to support your project from development through clinical supply.
Reference
- Webb C, et al. "Current Status and Future Perspectives on MRNA Drug Manufacturing" Mol. Pharmaceutics. 2022; 19 (4): 1047–1058.
